The overall goal is to study the effectiveness of SPECT imaging prostate cancer and breast cancer patients Using technetium-99m labeled RM26.~Phase I of the study:~Biodistribution of 99mTc-RM26 in patients with prostate cancer and breast cancer.~The main objectives of the study:~To evaluate the distribution of 99mTc-RM26 in normal tissues and tumors in patients with prostate cancer and breast cancer at different time intervals.~To evaluate dosimetry of 99mTc-RM26 based on the pharmacokinetic parameters of the drug after a single intravenous administration.~To study the safety of use and tolerability of the drug 99mTc-RM26 after a single intravenous administration in a diagnostic dosage.~Additional research tasks:~1. To conduct a comparative analysis of the diagnostic information obtained in the visualization of prostate cancer and breast cancer by SPECT using 99mTc-RM26 with data obtained by CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) research of postoperative material.~Methodology:~Open-label, exploratory, single centre study. The subjects will receive a single injection of the labeled tracer.
The study should evaluate the biological distribution of 99mTc-RM26 in patients with prostate cancer and breast cancer.~The primary objective are:~To assess the distribution of 99mTc- RM26 in normal tissues and tumors at different time intervals.~To evaluate dosimetry of 99mTc- RM26.~To study the safety and tolerability of the drug 99mTc- RM26 after a single injection in a diagnostic dosage.~The secondary objective are:~1. To compare the obtained 99mTc- RM26 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer and breast cancer patients.